SCHEMBL5982863

SCHEMBL5982863

CNC(=O)c1ccc2c(c1)n[c]n2C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.46
TDP1 Q9NUW8 1/20 0.43
ACSS2 Q9NR19 3/20 0.42
PLK1 P53350 1/20 0.42
AURKA O14965 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.41
PTGER4 P35408 1/20 0.41
RAB9A P51151 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CCNC P24863 1/20 0.40
HTR2A P28223 1/20 0.40
CDK8 P49336 1/20 0.40
PASK Q96RG2 1/20 0.40
CDK19 Q9BWU1 1/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
HDAC2 Q92769 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3648771 0.88 ACSS2 (0.49) THRBTDP1ACSS2PLK1AURKA
SCHEMBL5983851 0.83 FGFR1 (0.46) POLBMAPTHPGDRAB9ASMN1; SMN2
SCHEMBL5982464 0.83 HCAR3 (0.55) TDP1HPGD
SCHEMBL5981807 0.81 KDM4E (0.49) KMT2ASMN1; SMN2
SCHEMBL5983097 0.79 HPGD (0.42) ACSS2MAPTHPGDPTGER4SMN1; SMN2
SCHEMBL8360112 0.74 NAMPT (0.61) THRBPLK1MAPTHPGDRAB9A
SCHEMBL8032996 0.72 HPGD (0.44) MAPTHPGDRAB9AMEN1KMT2A
SCHEMBL4223848 0.71 ACSS2 (0.51) THRBTDP1ACSS2POLBMAPT
SCHEMBL3656285 0.70 FGFR1 (0.39) TDP1POLBMAPTRAB9AMEN1
SCHEMBL7474034 0.70 HTT (0.46) TDP1ACSS2MAPTHPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1634888-A2 Synthesis of 2'-deoxy-L-nucleosides Pharmasset Limited (US) 2006-03-15 EP disclosed
EP-1600452-A2 Synthesis of 2'-deoxy-L-nucleosides Pharmasset Limited (US) 2005-11-30 EP disclosed
EP-1600451-A2 Synthesis of 2'-deoxy-l-nucleosides Pharmasset Limited (US) 2005-11-30 EP disclosed
US-20050090660-A1 2'-deoxy-L-nucleosides PHARMASSET, INC. 2005-04-28 US disclosed
EP-1232166-A2 SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES Pharmasset Limited (US) 2002-08-21 EP disclosed
WO-2001034618-A2 SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES PHARMASSET LIMITED (US) 2001-05-17 WO disclosed
US-5614519-A (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists KARL THOMAE GMBH (DE) 1997-03-25 US disclosed
US-5602127-A ADMINISTERING TO TREAT HYPERTENSION KARL THOMAE GMBH (DE) 1997-02-11 US disclosed
US-5594003-A HYPOTENSIVE AGENTS DR. KARL THOMAE GMBH (DE) 1997-01-14 US disclosed
US-5591762-A HYPOTENSIVE AGENTS DR. KARL THOMAE GMBH (DE) 1997-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090660-A1 2'-deoxy-L-nucleosides CCNH, ADAR, NSUN2 THRB 2722/4885TDP1 4235/4885ACSS2 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.